Literature DB >> 21275495

Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.

Masha S H Lam1.   

Abstract

Oncology pharmacists face a constant challenge with patients who cannot swallow oral anticancer drugs, making extemporaneous oral liquid preparation a requirement. Improper extemporaneous preparation of these agents, especially with the traditional chemotherapy with a narrow therapeutic index, may increase the risk of over- or underdosing. In community pharmacies, multiple barriers exist that prevent these pharmacies from preparing extemporaneous oral anticancer drug formulations for a patient's use at home. In a home setting, patients or caregivers without proper counseling and education on how to safely handle chemotherapy are at increased risk for exposure to these drugs. Based on a review of the literature, compounding recipes are available for 46% of oral anticancer agents. A paucity of data exists on dose uniformity, bioequivalence, and stability of extemporaneous oral liquid formulations of anticancer drugs. Pharmacists must have an understanding of the basic scientific principles that are an essential foundation for the proper preparation of extemporaneous oral anticancer liquid formulations. The collaborative effort of a multidisciplinary team can also help identify different barriers in the community setting, especially in areas where community pharmacies may lack resources for the extemporaneous compounding of oral chemotherapy, and to find ways to coordinate better pharmaceutical care. There are great opportunities for oncology pharmacists, as well as community pharmacists, as a resource for educating and monitoring patients receiving oral chemotherapy to ensure dosing accuracy, safe administration, and proper disposal of hazardous drugs. Development of national guidelines to promote standards of practice in the community and/or home setting is urgently needed to help improve the safety of dispensing and handling oral chemotherapeutic agents, including extemporaneously compounded oral liquid formulations of these drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21275495     DOI: 10.1592/phco.31.2.164

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  11 in total

1. 

Authors:  Glen Brown
Journal:  Can J Hosp Pharm       Date:  2018-06-28

2.  The Value of Drug Stability Studies and Their Publication.

Authors:  Glen Brown
Journal:  Can J Hosp Pharm       Date:  2018-06-28

3.  Clinical pharmacy services in the outpatient pediatric oncology clinics at a comprehensive cancer center.

Authors:  Haitham W Tuffaha; Ola Abdelhadi; Suha Al Omar
Journal:  Int J Clin Pharm       Date:  2011-12-30

4.  Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

Authors:  Lia Gore; Pamela R Kearns; Maria Lucia de Martino; Carmino Antonio De Souza; Yves Bertrand; Nobuko Hijiya; Linda C Stork; Nack-Gyun Chung; Rocio Cardenas Cardos; Tapan Saikia; Franca Fagioli; Jong Jin Seo; Judith Landman-Parker; Donna Lancaster; Andrew E Place; Karen R Rabin; Mariana Sacchi; Rene Swanink; C Michel Zwaan
Journal:  J Clin Oncol       Date:  2018-03-02       Impact factor: 44.544

Review 5.  Inborn Errors of Metabolism in Pediatric Epilepsy.

Authors:  Anna S Cosnahan; Christopher T Campbell
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

6.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

7.  Pediatric Acute Promyelocytic Leukemia Presenting to the Emergency Department as Refusal to Ambulate.

Authors:  Kevin R Schwartz; Jennifer M Hanson; Alison M Friedmann
Journal:  Case Rep Emerg Med       Date:  2018-06-12

8.  Potassium canrenoate compounding for administration via enteral feeding tubes: a physical and microbiological stability study.

Authors:  Serena Logrippo; Matteo Sestili; Roberta Ganzetti; Giulia Bonacucina; Antonella Marziali; Patrizia Fattoretti; Silvia Busco; Alessandro Caraffa; Carlo Polidori; Giovanni Filippo Palmieri
Journal:  Eur J Hosp Pharm       Date:  2017-08-05

Review 9.  Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.

Authors:  Francesca Carofiglio; Antonio Lopalco; Angela Lopedota; Annalisa Cutrignelli; Orazio Nicolotti; Nunzio Denora; Angela Stefanachi; Francesco Leonetti
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

10.  Stability of temozolomide in solutions aimed for oral treatment prepared from a commercially available powder for infusion.

Authors:  Helen Nygren; Staffan Eksborg
Journal:  Pharm Methods       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.